Metagenomi reports Q2 2025 cash $205M; hemophilia A IND/CTA submission planned for 2026

Metagenomi Therapeutics, Inc.

2025-Q2 EPS reported -$1.21 vs consensus -$0.63 ▼ miss (-92.9%)

Cash, cash equivalents and marketable securities of $205.0M as of June 30, 2025; runway expected into 2027.
R&D expenses of $22.5M (down 20% YoY); G&A expenses of $7.0M (down from $8.6M).
MGX-001 hemophilia A program: IND/CTA submission planned in 2026; durable FVIII activity shown through 19 months in NHP study.
Appointed Laurence Reid, Ph.D., to Board of Directors in August 2025; established an R&D Committee.
Presented three abstracts at ASGCT on compact nucleases and CAST systems for targeted gene integration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.